<DOC>
	<DOCNO>NCT00177554</DOCNO>
	<brief_summary>The purpose study determine complete response rate CHOP-R chemotherapy follow Zevalin previous untreated patient follicular lymphoma</brief_summary>
	<brief_title>Phase II Trial CHOP-R Followed Zevalin Rituxan Follicular Lymphoma</brief_title>
	<detailed_description>Patients follicular lymphoma require therapy previously untreated eligible non-randomized , phase II study evaluate front therapy CHOP-R x 3 cycle follow zevalin 4 additional week rituxan.The complete response determine combine IWC criterion PET scanning.Secondary objective include PET-CT conversion rate , frequency severity adverse event , duration complete remission time next lymphoma therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Conformed diagnosis follicular lymphoma , grade 1,2 3 No prior chemotherapy No prior monoclonal antibody therapy Bulky symptomatic disease , stage IIIV Performance status 02 Impaired bone marrow reserve Presence CNS lymphoma Serious nonmalignant disease active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Non-Hodgkin Lymphoma</keyword>
</DOC>